The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Final results from PRIME: Randomized phase III study of panitumumab (pmab) with FOLFOX4 for first‑line metastatic colorectal cancer (mCRC).
J. Douillard
Consultant or Advisory Role - Amgen
Honoraria - Amgen
S. Siena
Consultant or Advisory Role - Amgen; AstraZeneca; Merck Serono; Roche
J. Cassidy
Consultant or Advisory Role - Amgen
Research Funding - Amgen
J. Tabernero
Consultant or Advisory Role - Amgen; ImClone Systems; Merck Serono; Roche
R. L. Burkes
Consultant or Advisory Role - Amgen
Honoraria - Amgen
M. E. Barugel
Consultant or Advisory Role - Amgen; Roche
Honoraria - Roche
Y. Humblet
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
D. Cunningham
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
F. Xu
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Krishnan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen